As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...

After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc. as CFO on Jan. 25. Frates said he felt a “calling” to do more to combat amyotrophic lateral sclerosis after his cousin...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its Phase III SOLOIST and SCORED trials of sotagliflozin could support an NDA submission as early as this year to reduce...

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes. The company now has an additional $50 million to move its first programs toward...

The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna...

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers.  Nick Leschly,...

After regaining worldwide rights to tislelizumab from Celgene Corp. in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis, which paid $650 million up front on Monday for rights in...

Editas Medicine Inc. (NASDAQ:EDIT) said CSO Charles Albright will depart Jan. 15 to pursue another opportunity. A search is under way to find a successor. Shares of the genome editing company fell 15% Monday to...